Northwest Biotherapeutics, Inc. (NWBO)
OTC Markets OTCQB · USD · Healthcare · Biotechnology
$0.1668 (-0.42%) as of
Key statistics
- Market cap
- 284.50M
- Forward P/E
- -2.38
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.1400 – 0.3400
- Beta
- -0.61
- Revenue (TTM)
- 2.17M
- Profit margin
- 0.00%
- Analyst target
- $1.00
- Volume
- 741.57k
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bethesda, MD, United States
- Employees
- 105
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.